<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30200142</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>01</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1536-5964</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>97</Volume>                    <Issue>36</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Medicine</Title>                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>            </Journal>            <ArticleTitle>Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study.</ArticleTitle>            <Pagination>                <MedlinePgn>e12222</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000012222</ELocationID>            <Abstract>                <AbstractText>The treatment of advanced triple-negative breast cancer, which failed in first-line or second-line therapy, is a significant challenge. We conducted this retrospective study to explore the efficacy and safety of apatinib and capecitabine as the third-line treatment for advanced triple-negative breast cancer.This retrospective study involved 44 advanced triple-negative breast cancer patients who failed in first-line or second-line therapy in Tangshan People's Hospital from January 2016 to February 2017. Twenty-two patients received apatinib and capecitabine, while 22 patients were treated with capecitabine monotherapy as third-line therapy. The progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events were compared between 2 groups.The apatinib and capecitabine group exhibited a higher PFS than capecitabine group (P = .001). Meanwhile, ORR and DCR in apatinib and capecitabine group were better than in capecitabine group (P = .042; .016). The 2 groups showed no significant difference in adverse events except degree I-II bleeding (P = .021). Both the apatinib and capecitabine and the capecitabine regimens revealed good tolerability.The apatinib and capecitabine regimen can achieve a better efficacy and similar serious adverse events compared with capecitabine regimen as the third-line treatment for advanced triple-negative breast cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Yi-Hui</ForeName>                    <Initials>YH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Multimodality Therapy Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhou</LastName>                    <ForeName>Yang</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Multimodality Therapy Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Yu-Wei</ForeName>                    <Initials>YW</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Multimodality Therapy Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tong</LastName>                    <ForeName>Ling</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Multimodality Therapy Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jiang</LastName>                    <ForeName>Run-Xue</ForeName>                    <Initials>RX</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Multimodality Therapy Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xiao</LastName>                    <ForeName>Lei</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Multimodality Therapy Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Guang-Ju</ForeName>                    <Initials>GJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Multimodality Therapy Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xing</LastName>                    <ForeName>Shu-Shan</ForeName>                    <Initials>SS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Multimodality Therapy Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Qian</LastName>                    <ForeName>Fang</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Multimodality Therapy Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Feng</LastName>                    <ForeName>Jing-Qi</ForeName>                    <Initials>JQ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Multimodality Therapy Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhao</LastName>                    <ForeName>Ya-Ling</ForeName>                    <Initials>YL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Multimodality Therapy Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Jian-Gong</ForeName>                    <Initials>JG</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Multimodality Therapy Oncology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Xiao-Hong</ForeName>                    <Initials>XH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemoradiotherapy, Tangshan People's Hospital, Tangshan, Hebei Province, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D003160">Comparative Study</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Medicine (Baltimore)</MedlineTA>            <NlmUniqueID>2985248R</NlmUniqueID>            <ISSNLinking>0025-7974</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>5S371K6132</RegistryNumber>                <NameOfSubstance UI="C553458">apatinib</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>6804DJ8Z9U</RegistryNumber>                <NameOfSubstance UI="D000069287">Capecitabine</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>AIM</CitationSubset>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 1999 Aug;35(8):1194-201</RefSource>                <PMID Version="1">10615229</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Pharmacol. 1998 Apr 1;55(7):1091-7</RefSource>                <PMID Version="1">9605432</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2011 Jul;102(7):1374-80</RefSource>                <PMID Version="1">21443688</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2014 Oct 15;135(8):1961-9</RefSource>                <PMID Version="1">24604288</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Apr 20;8(32):52813-52822</RefSource>                <PMID Version="1">28881773</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Asia Pac J Clin Oncol. 2018 Feb;14(1):32-39</RefSource>                <PMID Version="1">28815913</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2001 Sep;12(9):1247-54</RefSource>                <PMID Version="1">11697835</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2018 Jan;68(1):7-30</RefSource>                <PMID Version="1">29313949</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Lett. 2016 Mar 28;372(2):187-91</RefSource>                <PMID Version="1">26797419</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2005 Feb 10;23(5):1011-27</RefSource>                <PMID Version="1">15585754</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Tumour Biol. 2017 Jun;39(6):1010428317711033</RefSource>                <PMID Version="1">28639910</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2011 Mar 4;144(5):646-74</RefSource>                <PMID Version="1">21376230</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2009 Sep;45(13):2253-65</RefSource>                <PMID Version="1">19464166</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncology. 2010;79(5-6):331-6</RefSource>                <PMID Version="1">21430400</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Invest Dermatol. 2004 Jan;122(1):209-15</RefSource>                <PMID Version="1">14962110</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Aliment Pharmacol Ther. 2014 Oct;40(7):759-70</RefSource>                <PMID Version="1">25099956</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Rev Anticancer Ther. 2003 Apr;3(2):137-44</RefSource>                <PMID Version="1">12722873</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2011;16 Suppl 1:1-11</RefSource>                <PMID Version="1">21278435</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2010 Oct 05;10:529</RefSource>                <PMID Version="1">20923544</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2013 Sep 10;31(26):3219-25</RefSource>                <PMID Version="1">23918952</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2014 Nov 07;14:820</RefSource>                <PMID Version="1">25376790</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 1998 Nov;4(11):2755-61</RefSource>                <PMID Version="1">9829739</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2009 Feb;9(1):29-33</RefSource>                <PMID Version="1">19299237</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2010;12 Suppl 2:S3</RefSource>                <PMID Version="1">21050424</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2015 Feb 20;33(6):594-601</RefSource>                <PMID Version="1">25605862</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer. 2010 Oct;17(4):233-40</RefSource>                <PMID Version="1">19633909</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000069287" MajorTopicYN="N">Capecitabine</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName>                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30200142</ArticleId>            <ArticleId IdType="doi">10.1097/MD.0000000000012222</ArticleId>            <ArticleId IdType="pii">00005792-201809070-00084</ArticleId>            <ArticleId IdType="pmc">PMC6133618</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>